DR66 DataRelease
Release Date: June 2026
New Studies: 24
Updated Studies: 12
New Studies
| SDY2697: Investigation of booster vaccination of a novel HydroVax-panH1N1 vaccine | ||||||||||
| Status: | New | |||||||||
| Description: | To investigate the impact of booster vaccination on the magnitude, durability, breadth, and protective efficacy of a novel HydroVax-panH1N1 vaccine. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M36RRNL51Q | |||||||||
| Subjects: | 17 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: |
|
|||||||||
| Release Notes: |
|
|||||||||
| SDY3101: Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster | |||||||
| Status: | New | ||||||
| Description: | Here, the investigators perform neutralization assays on four viral variants (D614G, BA.5, XBB.1.5, and JN.1) using sera from participants obtained at 1 month, 3 months, and 6 months post an XBB.1.5 MV booster. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M37GRQSCWI | ||||||
| Subjects: | 92 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: |
|
||||||
| Release Notes: |
|
||||||
| SDY3261: RINSC vs RARAF Neutrons | ||||||||||
| Status: | New | |||||||||
| Description: | In the radiation biodosimetry field, transcriptomics studies seek to determine whether the expression of a small set of genes can be used to estimate the radiation dose that a person was exposed to. Most such studies consider only photon exposure, but in the detonation of an improvised nuclear device, neutrons would likely comprise a significant proportion of the dose. In this study, we compare the effects on gene expression in human blood between two neutron-producing radiation sources: a source designed to mimic the output of a nuclear weapon (the Columbia University Neutron Facility at the Radiological Research Acceleration Facility) and a source from a nuclear reactor (the Rhode Island Nuclear Science Center). The radiation sources have very different neutron energy spectra: mainly fast neutrons (Columbia source) versus thermal neutrons (Rhode Island source). Differential gene expression suggests that the fast neutron response comprises the thermal neutron response, plus an additional component, both in terms of number of differentially expressed genes and an analysis for overrepresented gene sets. This may be caused by the difference in neutron energies. An analysis of overrepresented gene sets using genes found to be correlated with radiation dose suggests a much more similar response between the results from the two different facilities with a difference in magnitude. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3X8YHSIYQ | |||||||||
| Subjects: | 12 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3322: 5 HA mRNA Candidate Data Package | |||||||
| Status: | New | ||||||
| Description: | We designed an mRNA-LNP vaccine expressing 5 HAs instead of 20 HAs. This 5 HA mRNA-LNP will be used in a Phase 1 clinical study. This vaccine encodes H1, H2, H3, H5, and H7 immunogens. We updated the H1, H3, H5, and H7 components relative to the respective components of the 20 HA mRNA-LNP vaccine. For initial pre-clinical immunogenicity studies, we created 5 separate monovalent HA mRNA-LNP and mixed these LNPs prior to vaccination. This was the same procedure that was used for our 20 HA mRNA-LNP pre-clinical studies. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M35VOTL4RZ | ||||||
| Subjects: | 47 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: |
|
||||||
| Release Notes: |
|
||||||
| SDY3353: Human Immune Responses to Different Covid-19 Vaccines | ||||||||||
| Status: | New | |||||||||
| Description: | mRNA vaccines, administered in two doses, have been very effective against SARS-CoV-2 and are considered for broader vaccine applications. However, the development of human innate immune responses to these novel vaccines remains incompletely understood. Here, we profiled immune responses to Pfizer’s BNT162b2Ò (n=22) and Moderna’s mRNA-1273Ò (n=6), compared to J&J’s adenoviral vector vaccine Ad26.COV2.SÒ (n=3), using longitudinal single-cell profiling of peripheral blood mononuclear cells (PBMCs). The first dose of the mRNA vaccines induced a unique interferon state (ISGdim) in monocytes and dendritic cells, marked by upregulation of MX1, MX2, DDX58 (RIG-I), and other genes regulated by the ISGF3 (Interferon-Stimulated Gene Factor 3) complex. This ISGdim state transitioned into a full interferon-stimulated gene state (ISGhigh) after the second dose, characterized by the upregulation of additional interferon-responsive genes (e.g., XXX). In vitro experiments revealed that while the ISGdim state is driven by endogenous IFN-α production, IFN-γ is required to establish the ISGhigh state. Collectively, this study provides key insights into the stepwise development of innate immune responses to mRNA vaccines in human myeloid cells. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3NPY1LH69 | |||||||||
| Subjects: | 32 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: | None | |||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3439: Gene discovery and expression analysis of the B cell receptor repertoire in the domestic ferret model | ||||||||||
| Status: | New | |||||||||
| Description: | The domestic ferret is the preferred model organism for the study of influenza A infection and responses to vaccination but has remained underutilized in antibody-omics research to inform vaccine design. This study used a curated set of V(D)J genes from human and closely related carnivores to BLAST the ferret genome to define a reference immunoglobulin repertoire for the ferret. Immunoglobulin transcript expression was analyzed for both variable and constant region genes to identify two functional IGHG genes in the ferret. A publicly available workflow for discovering immunoglobulin genes in any species is now available, as well as a complete ferret immunoglobulin gene set with genomic sequences for 409 heavy and light chain ferret immunoglobulin genes. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M31DN6EGLY | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3652: Monitoring radiation exposure through skin swab metabolomic profiling | ||||||||||
| Status: | New | |||||||||
| Description: | Exposure to ionizing radiation poses major health risks across medical, occupational, and spaceflight settings, driving the need for rapid, non-invasive biodosimetry tools. As the body’s most accessible organ and the most frequent site of radiation injury, the skin represents a promising interface for monitoring exposure. Using murine models, we performed metabolomic profiling on skin swab samples collected after exposure to 0, 1, or 4 Gy of x-rays. We identified two distinct metabolite panels: one discriminating irradiated from non-irradiated skin, and another distinguishing dose-specific response. These panels included conserved radiation-responsive metabolites (e.g., uric acid, xanthine, taurine) and skin-specific markers associated with barrier integrity (e.g., proline, arginine). These findings establish a foundation for non-invasive and real-time skin-based biodosimetry approaches for radiation exposures. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3A2O48ZV7 | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: | None | |||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3682: 17q12-q21 Genotype, Viral Wheezing and Childhood Asthma | |||||||||||||||||||||||||
| Status: | New | ||||||||||||||||||||||||
| Description: | Early-life viral wheezing illnesses and 17q12-q21 genotypes are associated with childhood asthma. In five cohorts of the Children’s Respiratory and Environmental Workgroup (CREW), we studied the association of 17q12-q21 genotypes with RV and/or RSV virus-specific wheezing in the first three years of life within each of two parent-identified racial groups, White and Black children. We then evaluated 17q12-q21 genotype and virus-specific wheezing on asthma outcomes at ages five to seven years. We assessed how genotype modified associations of viral wheezing illness on the prevalence of asthma stratified by parental asthma history. The rs7216389-TT asthma risk genotype was associated with increased cumulative RV-wheezing events to age three years in White (hazard ratio 1.46 [95%CI: 1.16, 1.85]) but not in Black children; genotype did not increase risk for RSV-wheezing in White or Black children. An interaction effect of rs7216389 genotype RV wheeze on asthma risk was present in Black children (PInt = 0.017) and with RSV wheeze in White children (PInt = 0.018). When stratified by parental asthma there were similar interaction effects of rs7216389 genotype with RV (PInt = 0.046) or RSV (PInt < 0.001) wheezing illnesses on asthma risk only in children without a parental history of asthma. For all interaction effects, the asthma risk genotype at rs7216389 was associated with increased risk of asthma among children without a virus-specific wheezing illness but was associated with lower risk of asthma among children with a virus-specific wheezing illness. Virus induced wheezing illnesses reduced the risk for asthma in certain subgroups of children. 17q12-q21 genotype interactions on asthma risk varied by race, virus-strain and parental asthma, highlighting the complexity of this locus and childhood asthma. | ||||||||||||||||||||||||
| Program/Contract: |
|
||||||||||||||||||||||||
| DOI: | 10.21430/M3GWMGFRQ5 | ||||||||||||||||||||||||
| Subjects: | 0 | ||||||||||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||||||||||
| Publications: |
|
||||||||||||||||||||||||
| Resources: |
|
||||||||||||||||||||||||
| Assays: | None | ||||||||||||||||||||||||
| Clinical Assessments: | None | ||||||||||||||||||||||||
| Release Notes: |
|
||||||||||||||||||||||||
| SDY3683: COBRA and cGAMP Microparticles Provide Active and Stable Vaccine Platform | |||||||
| Status: | New | ||||||
| Description: | An acetalated dextran microparticle influenza vaccine encapsulating a broadly reactive COBRA hemagglutinin antigen and the STING agonist cGAMP was evaluated in mice, where it induced broadly neutralizing antibody responses, strong cellular immunity, and maintained immunogenicity after storage outside of cold-chain conditions, addressing key limitations of current influenza vaccines related to stability and variable efficacy. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M39AGJY7HV | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3684: TRAC478 and saponin adjuvant enhance immune responses elicited by COBRA HA | ||||||||||||||||
| Status: | New | |||||||||||||||
| Description: | COBRA H1 and H3 HA proteins were formulated with two adjuvant systems, TRAC478 emulsion and SAS. These COBRA HA antigen and adjuvant combinations were evaluated for their ability to elicit antigen-specific humoral and cellular immune responses against panels of historical H1N1 and H3N2 vaccine strains and compared to immune responses elicited by unadjuvanted HA subunit vaccines in influenza naive mice. The performance of these vaccine candidates were also evaluated in pre-immune ferrets. | |||||||||||||||
| Program/Contract: |
|
|||||||||||||||
| DOI: | 10.21430/M3SQHGIDJJ | |||||||||||||||
| Subjects: | 0 | |||||||||||||||
| Study PI, contact: |
|
|||||||||||||||
| Publications: |
|
|||||||||||||||
| Resources: |
|
|||||||||||||||
| Assays: | None | |||||||||||||||
| Clinical Assessments: | None | |||||||||||||||
| Release Notes: |
|
|||||||||||||||
| SDY3686: Synthetic DNA co-immunization with vaccine-aligned common consensus nucleoprotein and hemagglutinin protects mice against lethal influenza infection with a single immunization | ||||||||||
| Status: | New | |||||||||
| Description: | The authors engineered synthetic DNA vaccine candidates encoding vaccine-aligned common consensus (VACC) immunogens designed to represent the immune diversity of seasonal H1N1 and H3N2 virus NP proteins, and tested them in a high-dose challenge mouse model | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3THIZLR7B | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3687: Administration of Influenza Hemagglutinin in One Leg Elicits Similar Immune Responses as in Two Legs | |||||||
| Status: | New | ||||||
| Description: | Intramuscular vaccination of COBRA H1 and or H3 HA proteins in two distinct locations were compared to a single injection site in mice. B cell activation, antibody response and viral protection were evaluated to determine if increasing the distribution of antigen would increase immune responses. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3S4XS4FZ6 | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3689: GI-ARS Efficacy Study in Rhesus Macaques after Partial Body Irradiation (PBI/BM5) - Control Animals | |||||||
| Status: | New | ||||||
| Description: | Prior to irradiation, NHP were randomized to either a control (n = 15) or treated (n = 15) cohort. On Study Day (SD) 0, each NHP was sedated, restrained, and transported to the LINAC facility. They were then placed on the LINAC treatment table and positioned within the lighted radiation field in such a way that the whole body was contained within the field, with the exception of the tibiae, ankles, and feet (i.e., the field terminated at the inferior edge of the patella). After positioning, the NHPs were exposed to six (6) megavolt (MV) photons delivered at a dose rate of approximately 0.80 Gy/min, resulting in PBI/BM5 to a targeted dose of 12.0 Gy. Following irradiation, NHP were administered six (6) SC injections of either TA or CA (10 mM histidine buffer in water at 0.1 ml/kg) at 24 ± 2 hour intervals from the time of irradiation. All animals were monitored for complete blood count (CBC), plasma levels of blood urea nitrogen (BUN) and creatinine (Cr), body weight (BW), rectal body temperature (RBT), stool consistency, and clinical hydration status through the end of the in-life phase. Animals received medical management consisting of intravenous (IV) fluids, antibiotics, analgesics, antidiarrheals, antiemetics, blood transfusions, supplemental nutrition, and other support as required. rhesus macaques, Macaca mulatta, radiation, natural history, radiation sickness, gastrointestinal, hematology, histology, cytokines, RNCP Animals were euthanized according to a set of criteria based on clinical signs including activity level, weight loss, and responsiveness to antidiarrheal treatment, or between SD31 and SD35 if criteria were not met during the in-life phase. Survival was analyzed at 15 and 30 days postirradiation. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3WHI3TIET | ||||||
| Subjects: | 15 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3690: Optimizing delivery in subunit influenza vaccine using mixed microparticle degradation rates | |||||||
| Status: | New | ||||||
| Description: | Development of a multivalent influenza vaccine using acetalated dextran microparticles (Ace-DEX MPs) to deliver broadly reactive antigens and adjuvants. By tuning the degradation rates of these particles, researchers enhanced immune responses and reduced antigen dominance, showing promising protection against multiple flu strains in animal models. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3IZ6E0R6K | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3692: SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1 | |||||||
| Status: | New | ||||||
| Description: | Here, the authors characterized the antibody evasion, ACE2 receptor engagement, and viral infectivity of the highly mutated SARS-CoV-2 Omicron subvariant BA.2.87.1 in comparison to other Omicron subvariants. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3GFL7HC0D | ||||||
| Subjects: | 40 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: |
|
||||||
| Release Notes: |
|
||||||
| SDY3693: Electroporation and LNP-mediated delivery of plasmid DNA-encoded H5N1 influenza virus hemagglutinin support protection against highly pathogenic avian influenza | ||||||||||
| Status: | New | |||||||||
| Description: | The authors describe the generation of emergent H5 HPAI hemagglutinin (HA) DNA plasmids and characterize their immunogenicity and protective efficacy in lethal HPAI mouse challenge models | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M34J55Y3M7 | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3694: Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses | ||||||||||
| Status: | New | |||||||||
| Description: | The authors describe a ferret model to mimic the serial exposure of humans to antigenically different historical H3HA proteins | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3ILV6O73Y | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3695: Preclinical evaluation of DNA and mRNA-LNP H5N1 influenza vaccines | |||||||
| Status: | New | ||||||
| Description: | Mouse studies were conducted to assess antibody responses, viral challenge protection, and immune correlates following vaccination with DNA or mRNA-LNP constructs expressing full-length H5 hemagglutinin and neuraminidase derived from a contemporary clade 2.3.4.4b H5N1 virus. Vaccinated animals were evaluated for serological responses and survival following homologous viral challenge. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M30Z0ETB3H | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3696: Vaccination with antigenically complex hemagglutinin mixtures confers broad protection from influenza disease | |||||||||||||||
| Status: | New | ||||||||||||||
| Description: | Current seasonal influenza vaccines mainly elicit antibodies against highly variable epitopes in the HA head, requiring frequent updates due to antigenic drift. To broaden protection, we developed a complex mixture of recombinant HA antigens designed to shift immune responses toward more conserved regions of the protein. This approach enhanced antibody targeting of the HA stalk while maintaining or improving responses to the head domain. In animal models, these changes translated into better protection against both matched and mismatched viral strains compared to conventional vaccines. These findings suggest that antigenically diverse HA formulations can reduce head-domain immunodominance and represent a promising step toward universal influenza vaccine strategies. | ||||||||||||||
| Program/Contract: |
|
||||||||||||||
| DOI: | 10.21430/M3Y7T8DDKG | ||||||||||||||
| Subjects: | 257 | ||||||||||||||
| Study PI, contact: |
|
||||||||||||||
| Publications: |
|
||||||||||||||
| Resources: |
|
||||||||||||||
| Assays: |
|
||||||||||||||
| Clinical Assessments: |
|
||||||||||||||
| Release Notes: |
|
||||||||||||||
| SDY3697: Comparison of IgK and IgL binding toward influenza virus hemagglutinin and SARS-CoV-2 Spike protein during primary viral infections | |||||||||||||||||||
| Status: | New | ||||||||||||||||||
| Description: | It has been identified in ferrets a light chain bias (IgL) in ferrets after influenza virus infection. To investigate if the light chain bias phenotype is consistent between species, serum immunoglobulin in humans, mice and pigs following virus infection were evaluated. The binding capacity to the immunodominant viral glycoprotein of the infecting virus of each IgL population was tested. | ||||||||||||||||||
| Program/Contract: |
|
||||||||||||||||||
| DOI: | 10.21430/M3DOG8R1BT | ||||||||||||||||||
| Subjects: | 0 | ||||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||||
| Publications: |
|
||||||||||||||||||
| Resources: |
|
||||||||||||||||||
| Assays: | None | ||||||||||||||||||
| Clinical Assessments: | None | ||||||||||||||||||
| Release Notes: |
|
||||||||||||||||||
| SDY3699: mRNA-based influenza vaccine expands the B cell response breadth in humans | |||||||
| Status: | New | ||||||
| Description: | The authors assessed B cell responses in an observational study of cohorts of healthy young adults receiving a licensed, split-virion or investigative mRNA-based quadrivalent seasonal influenza virus vaccine over two consecutive seasons | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3EPB0IASJ | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3700: Correlation of Binding and Neutralizing Antibodies to SARS-CoV-2 Omicron after BNT162b2 Vaccination | |||||||
| Status: | New | ||||||
| Description: | Adults vaccinated with BNT162b2 in 2020-2021 were stratified as infection-naive (n=29) or convalescent (n=27). Plasma was tested at baseline, 3 weeks after dose 1 (T1), and 1 month after dose 2 (T2) using MSD anti-spike IgG (reported in BAU/mL) and Abbott anti-RBD IgG, and Duke pseudovirus neutralization (ID50) against D614G, Beta, Delta, and Omicron (BA.1). Convalescent participants had higher binding IgG at all timepoints. Binding and neutralization correlated strongly overall; however, a larger fraction had undetectable Omicron neutralization even when binding IgG was positive. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3YL9BWQ47 | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3701: Human monoclonal antibodies that target clade 2.3.4.4b H5N1 hemagglutinin | ||||||||||
| Status: | New | |||||||||
| Description: | The authors generated a panel of anti-hemagglutinin (HA) human monoclonal antibodies (mAbs) against the H5 protein of clade 2.3.4.4b. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M37L56TQGR | |||||||||
| Subjects: | 1 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3702: T cell population correlates | ||||||||||
| Status: | New | |||||||||
| Description: | Correlates of protection against symptomatic influenza virus infection | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3MQJHHU58 | |||||||||
| Subjects: | 206 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: |
|
|||||||||
| Release Notes: |
|
|||||||||
Updated Studies
| SDY621: Registry for the Atopic Dermatitis Research Network (ADRN-02) | ||||||||||
| Status: | Updated | |||||||||
| Description: | People with atopic dermatitis (AD), also known as eczema, experience hot, dry, scaly skin with severe itching. In addition, people with AD are prone to skin infections and inflammation. Little is known about the causes of AD or why people with AD are more prone to infections. The purpose of this multi-center, clinical registry study is to determine genetic markers associated with susceptibility of AD patients to infections and to also serve as a potential participant database for future studies. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3BWTEJ0L4 | |||||||||
| Subjects: | 3611 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: | None | |||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY1190: Single-cell RNA-Seq analysis of MTB and DENV immune responses | |||||||
| Status: | Updated | ||||||
| Description: | Single-cell RNA-Seq assays were performed to precisely define the transcriptional profile of Dengue virus (DENV) and Mycobacterium tuberculosis (MTB) antigen specific CD4 T cells. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3IFOL9MKV | ||||||
| Subjects: | 16 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY1854: GI-ARS Efficacy study (180 Days) of Subcutaneous Filgrastim (PBI/BM5) in Rhesus Macaques after Partial Body Irradiation | ||||||||||||||||||
| Status: | Updated | |||||||||||||||||
| Description: | Rhesus macaques were exposed to partial-body irradiation with 5% bone marrow sparing to assess the effect of Neupogen (filgrastim, granulocyte colony stimulating factor [G-CSF]) to mitigate the associated myelosuppression when administered at 24, 72, or 120 hourse post irradiation. A secondary objective was to assess the effect of Neupogen on the mortality or morbidity of the hematopoietic (H)- acute radiation syndrome (ARS) and concomitant acute gastrointestinal radiation syndrome (GI-ARS), prolonged GI injury, acute and chronic kidney injury (AKI, CKI respectively) and delayed lung injury characteristic of delayed effects of acute radiation exposure (DEARE). NHP were exposed to 10 (N=20 males) or 11 Gy (N=28 males) with 6 MV LINAC-derived photons at approximately 0.80 Gy/min. All NHP received medical management. NHP were dosed daily with control article (5% dextrose in water) initiated on day 1 post-exposure or Neupogen (10 ug/kg) initiated on day 1, day 3, or day 5 until recovery (absolute neutrophil count [ANC] >= 1,000 cells/uL for 3 consecutive days). Keywords: rhesus macaques, Macaca mulatta, radiation, natural history, radiation sickness, hematopoietic, gastrointestinal, lung, hematology, metabolomics, histology, filgrastim, RNCP |
|||||||||||||||||
| Program/Contract: |
|
|||||||||||||||||
| DOI: | 10.21430/M3ZE7NMJN9 | |||||||||||||||||
| Subjects: | 48 | |||||||||||||||||
| Study PI, contact: |
|
|||||||||||||||||
| Publications: |
|
|||||||||||||||||
| Resources: |
|
|||||||||||||||||
| Assays: |
|
|||||||||||||||||
| Clinical Assessments: | None | |||||||||||||||||
| Release Notes: |
|
|||||||||||||||||
| SDY1997: GI-ARS and H-ARS Dose-Response Relationship in Rhesus Macaques after Partial Body Irradiation | ||||||||||||||||||
| Status: | Updated | |||||||||||||||||
| Description: | The primary objective of this study is to determine the 60 day survival of rhesus macaques after irradiation to an approximate LD50/8-10 with tibial shielding and receiving medical management. These data were used to determine whether approximately 5% marrow sparing will allow spontaneous regeneration of the hematopoietic system subsequent to an otherwise supra-lethal dose of total-body irradiation and recovery from the acute GI radiation syndrome (GI-ARS). This model formed part of an non-human primate research platform used in subsequent studies to examine the effects of radiomitigating drugs on long-term survival of rhesus macaques after irradiation at the LD50/8-10 to induce GI syndrome with minimal marrow shielding and medical management. Animals were evaluated to Day 60 to evaluate the heme and GI syndromes and up to approximately Day 180 to evaluate the delayed effects of acute radiation exposure (DEARE). rhesus macaques, Macaca mulatta, radiation, natural history, radiation sickness, hematopoietic, gastrointestinal, lung, hematology, histology, metabolomics, RNCP |
|||||||||||||||||
| Program/Contract: |
|
|||||||||||||||||
| DOI: | 10.21430/M3RNEV8J4M | |||||||||||||||||
| Subjects: | 58 | |||||||||||||||||
| Study PI, contact: |
|
|||||||||||||||||
| Publications: |
|
|||||||||||||||||
| Resources: |
|
|||||||||||||||||
| Assays: |
|
|||||||||||||||||
| Clinical Assessments: | None | |||||||||||||||||
| Release Notes: |
|
|||||||||||||||||
| SDY2002: Natural History of the Gastrointestinal Acute Radiation Syndrome (GI-ARS) in Rhesus Macaques Following Partial Body Irradiation (2.5% Bone Marrow Sparing) | |||||||||
| Status: | Updated | ||||||||
| Description: | A nonhuman primate model of acute, partial-body, high dose, irradiation (6 megavolt linear accelerator-derived photons delivered at 0.80 Gy minute-1) with 2.5% bone marrow sparing was used to assess the severity and natural history of the acute GI-ARS and associated, concurrent H-ARS and AKI consequent to 12 Gy irradiation. The primary endpoint was survival and secondary objectives focused on a) natural history components and morbidity of GI-ARS (d1-30 post exposure), b) acute kidney injury (AKI, d1-30+ post exposure), c) available database for lung and heart, d) organ-specific biomarkers: plasma- and tissue-based biomarkers for radiation dose and multi-organ injury. Assess the ability to predict DEARE (lung, heart, prolonged GI, kidney). All animals received subject-based medical management. rhesus macaques, Macaca mulatta, radiation, natural history, radiation sickness, hematopoietic, gastrointestinal, lung, hematology, histology, metabolomics, proteomics, lipidomics, bile acid, RNCP |
||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3TQH2ZN7E | ||||||||
| Subjects: | 42 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| Release Notes: |
|
||||||||
| SDY2058: GI-ARS Efficacy study (180 Days) of Subcutaneous Filgrastim or Pegfilgrastim in Rhesus Macaques after Partial Body Irradiation (PBI/BM2.5) | |||||||
| Status: | Updated | ||||||
| Description: | Rhesus macaques were exposed to partial-body irradiation with 2.5% bone marrow sparing to assess the effect of Neupogen (filgrastim, granulocyte colony stimulating factor [G-CSF]) or Neulasta (pegfilgrastim, pegG-CSF) to mitigate the associated myelosuppression when administered at 24 or 72 hours post irradiation. A secondary objective was to assess the effect of Neupogen or Neulasta on the mortality or morbidity of the hematopoietic (H)- acute radiation syndrome (ARS) and concomitant acute gastrointestinal radiation syndrome (GI-ARS), prolonged GI injury, acute and chronic kidney injury (AKI, CKI respectively) and delayed lung injury characteristic of delayed effects of acute radiation exposure (DEARE). NHP were exposed to 10 Gy with 6 MV LINAC-derived photons at approximately 0.80 Gy/min. All NHP received medical management. NHP were dosed daily or weekly with control article (5% dextrose in water, or D5W), daily with Neupogen, or weekly with Neulasta. D5W was initiated on day 1 post-exposure. Neupogen (10 ug/kg) administration was initiated on days 1 or 3 post-exposure until recovery (absolute neutrophil count [ANC] >= 1,000 cells/uL for 3 consecutive days). Neulasta (300 ug/kg) administration was initiated on day 1 (days 1, 8, 15) or day 3 (days 3, 11, 17). Keywords: rhesus macaques, Macaca mulatta, radiation, natural history, radiation sickness, hematopoietic, gastrointestinal, lung, hematology, metabolomics, filgrastim, pegfilgrastim, RNCP |
||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3CXBS8APJ | ||||||
| Subjects: | 44 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY2532: Germinal centre-driven maturation of B cell response to SARS-CoV-2 vaccination | |||||||||||
| Status: | Updated | ||||||||||
| Description: | The maturation dynamics of GC B cells and propagation of their progeny throughout the B cell diaspora have not been elucidated, therefore, here we show that anti-SARS-CoV-2 spike (S)-binding GC B cells were detectable in draining lymph nodes in those that were vaccinated against SARS-CoV-2. Using a combined approach of single-cell RNA sequencing of responding blood and lymph node B cells from eight participants and expression of the corresponding monoclonal antibodies, we tracked the evolution of 1540 S-specific B cell clones. This study documents the induction of affinity-matured BMPCs after two doses of SARS-CoV-2 mRNA vaccination in humans, providing a foundation for the sustained high efficacy observed with these vaccines. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3818VPQQM | ||||||||||
| Subjects: | 43 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: |
|
||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: |
|
||||||||||
| Release Notes: |
|
||||||||||
| SDY2809: Nasally delivered interferon lambda protects mice against SARS-CoV-2 infection | |||||||||
| Status: | Updated | ||||||||
| Description: | Here, we show that IFN-l protects against SARS-CoV-2 B.1.351 (Beta) and B.1.1.529 (Omicron) variants in three strains of conventional and human ACE2 transgenic mice | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3FGEA29GM | ||||||||
| Subjects: | 325 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: |
|
||||||||
| Release Notes: |
|
||||||||
| SDY3173: Sequential immunization with chimeric hemagglutinin del-NS1 attenuated influenza vaccines induces broad humoral and cellular immunity | |||||||||
| Status: | Updated | ||||||||
| Description: | Mice were intranasally administered cH8/1-del-NS1 followed by a cH11/1-del-NS1 heterologous booster, then challenged with seasonal H1N1 influenza virus and heterologous highly pathogenic avian H5N1. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3QJKM5VTT | ||||||||
| Subjects: | 223 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: |
|
||||||||
| Release Notes: |
|
||||||||
| SDY3244: Influenza vaccination stimulates maturation of the human T follicular helper cell response | |||||||
| Status: | Updated | ||||||
| Description: | The differentiation and specificity of human CD4+ T follicular helper cells (TFH cells) after influenza vaccination have been poorly defined. Here we profiled blood and draining lymph node (LN) samples from human volunteers for over 2 years after two influenza vaccines were administered 1 year apart to define the evolution of the CD4+ TFH cell response. The first vaccination induced an increase in the frequency of circulating TFH (cTFH) and LN TFH cells at week 1 post-vaccination. This increase was transient for cTFH cells, whereas the LN TFH cells further expanded during week 2 and remained elevated in frequency for at least 3 months. We observed several distinct subsets of TFH cells in the LN, including pre-TFH cells, memory TFH cells, germinal center (GC) TFH cells and interleukin-10+ TFH cell subsets beginning at baseline and at all time points post-vaccination. The shift toward a GC TFH cell phenotype occurred with faster kinetics after the second vaccine compared to the first vaccine. We identified several influenza-specific TFH cell clonal lineages, including multiple responses targeting internal influenza virus proteins, and found that each TFH cell state was attainable within a clonal lineage. Thus, human TFH cells form a durable and dynamic multi-tissue network. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3YO7X2FEQ | ||||||
| Subjects: | 5 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3303: Influenza T cell response post-vaccination | |||||||
| Status: | Updated | ||||||
| Description: | To understand and identify changes in the profile of influenza strain-specific T cells from days 3 to 28 post immnunization with Fluzone. The strain-specific correlations of cellular immnunity to influenza with plasma analytes and serological immnunity were also analyzed. Quantification and phenotyping of influenza strain-specific T cells were performed, as well as plasma analyte profiling by Luminex. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3UNIMUM1W | ||||||
| Subjects: | 37 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3504: Breast milk antibody Fc features linked to HIV transmission during breastfeeding | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | Breastfeeding shapes early immunity, but without antiretroviral therapy (ART), carries a risk of HIV transmission. The role of breast milk antibodies in this process remains unclear. Using systems serology, we profiled milk antibodies from transmitting and non-transmitting mothers in the Zambia Exclusive Breastfeeding Study. Transmission was linked to higher gp41-specific IgG1 and increased effector functions — including complement deposition (ADCD) and neutrophil phagocytosis (ADNP) — likely driven by elevated milk viral loads. In contrast, non-transmitting mothers showed p24-specific antibody responses inversely correlated with lower viral loads, suggesting better viral control. Fc glycosylation analysis revealed higher digalactosylated IgG in transmitting mothers, linked to enhanced neutrophil inflammatory cytokine release. IgG depletion experiments confirmed that IgG, not IgA, was the primary driver of neutrophil activation in transmitting mothers. Overall, these findings highlight distinct humoral immune signatures associated with HIV transmission risk or protection during breastfeeding and provide mechanistic insights relevant for maternal vaccine development and Fc-engineered broadly neutralizing antibody prevention strategies. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M36HEJZR0A | ||||||||||||
| Subjects: | 100 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| Release Notes: |
|
||||||||||||